Karuna

THERAPEUTIC AREA

Schizophrenia and Alzheimer's disease psychosis

YEAR INVESTED

2019

STAGE

IPO'd in 2019; acquired by Bristol Myers Squibb

WEBSITE

karunatx.com  ↗

Karuna Therapeutics is a clinical-stage company targeting muscarinic cholinergic receptors, a novel therapeutic modality for the treatment of psychosis and cognitive impairment across central nervous system disorders. Karuna’s lead candidate, KarXT, has demonstrated positive phase three data in schizophrenia.